ATG-F与OKT3在肾移植术后急性排斥反应中的应用研究  

Clinical application of ATG-F and OKT3 in posttransplant patients with acute rejection

作　　者：常征[1] 郝俊文[1] 张爱民[1] Chang Zheng Hao Junwen Zhang Aimin.(Department of Urology, General Hospital of Jinan Military Command, Jinan 250031, China)

机构地区：[1]济南军区总医院泌尿外科,山东济南250031

出　　处：《国际泌尿系统杂志》2017年第3期415-418,共4页International Journal of Urology and Nephrology

摘　　要：目的 探讨应用注射用兔抗人T淋巴细胞多克隆抗体（ATG-F）及注射用抗人T细胞CD3鼠单克隆抗体（OKT3）治疗肾移植术后急性排斥反应的效果、安全性和副反应等.方法 本中心施行同种异体肾移植术后对于激素冲击治疗不敏感的急性排斥患者51例,分为两组,分别给予多克隆抗体ATG-F和单克隆抗体OKT3治疗,并对治疗效果、安全性和药物的副反应等进行统计学分析.结果 ATG-F治疗28例,排斥逆转26例,治愈率89.3％;OKT3抗组23例,排斥逆转16例,治愈率69.6％.两组结果间有显著性差异（P＜0.05）.结论 OKT3和ATG-F同为抗淋巴细胞的抗体,但其针对难治性急性排斥反应的治疗效果,存在明显差异.ATG-F临床效果肯定,并且用量灵活,副作用小.OKT3治疗效果一般,则具有术后感染发生率增加、白细胞减少等并发症.Objectives To investigate the effect and reliability of ATG-F polyclonal antibody and OKT3 monoclonal antibody treatment for posttransplant patients with acute rejection（AR）.Methods A total of 51 patients with acute rejection who underwent renal transplantation and methyprednisolone impulsing therapy were divided into two groups.They received ATG-F polyclonal antibody and OKT3 monoclonal antibody treatment to prevent acute rejection respectively.A statistical analysis of treatment effects,safety and side effects of drugs was conducted.Results The rejection reverse rates in OKT3 and ATG-F group were 69.6% and 83.9%,respectively （P 〈 0.05）.Conclusions As the therapeutic medicine to AR after transplantation,OKT3 and ATG-F can reverse AR very well.It can rescue some of patients from losing allograft as a result of AR.But as a kind of foreign protein,OKT3 can lead to many side effects such as increasing infection rate and？ leucopenia.Overall,the therapeutic effect of ATG-F is better than that of OKT3.

关 键 词：肾移植 抗体 移植物排斥 

分 类 号：R699.2[医药卫生—泌尿科学]